Meanwhile, TRIM31 inhibits MDM2-mediated K48 ubiquitination by competitively inhibiting the MDM2-p53 interaction, resulting in the stability and activation of p53, thus inhibiting the proliferation, migration, and invasion of breast cancer cells (Guo et al., 2021). Here, TRIM31 is linked to breast carcinoma.